Sodium Zirconium Cyclosilicate — Membership Pricing

Other medications in Nephrology

• Sucroferric Oxyhydroxide
• Lanthanum Carbonate
• Patiromer
• Sevelamer

About Sodium Zirconium Cyclosilicate

Sodium zirconium cyclosilicate is a prescription medication used to treat hyperkalemia, a condition characterized by dangerously high potassium levels in the blood. Managing this condition is crucial for your health. At TheDrugClub, we understand the importance of affordable access to vital medications. We're dedicated to helping our members find significant savings on prescriptions like sodium zirconium cyclosilicate.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sodium Zirconium Cyclosilicate is approved for (FDA label)

LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. ( 1 ) Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: March 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sodium Zirconium Cyclosilicate (FDA label)

For oral suspension: 5 g or 10 g of white to grey powder in a foil-lined packet. • For oral suspension: 5 g per packet ( 3 ) • For oral suspension: 10 g per packet ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8. SPL document ID: 5bb5ae7d-0be6-4ecc-bb31-4eedd2f724b9. Label effective date: March 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sodium Zirconium Cyclosilicate (FDA label)

The following adverse reactions are discussed in greater detail elsewhere in the label: • Edema [see Warnings and Precautions (5.2) ] . Most common adverse reactions with LOKELMA: mild to moderate edema. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8. SPL document ID: 5bb5ae7d-0be6-4ecc-bb31-4eedd2f724b9. Label effective date: March 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sodium Zirconium Cyclosilicate (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8. SPL document ID: 5bb5ae7d-0be6-4ecc-bb31-4eedd2f724b9. Label effective date: March 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sodium Zirconium Cyclosilicate (FDA label)

• Gastrointestinal Adverse Events in Patients with Motility Disorders. ( 5.1 ) • Edema. ( 5.2 ) • Hypokalemia in patients on hemodialysis. ( 5.3 ) • LOKELMA has radio-opaque properties and, therefore, may give the appearance typical of an imaging agent during abdominal X-ray procedures. ( 5.4 ) 5.1 Gastrointestinal Adverse Events in Patients with Motility Disorders Avoid use of LOKELMA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because LOKELMA has not been studied in patients with these conditions and may be ineffective and may worsen gastrointestinal conditions. 5.2 Edema Each 5 g dose of LOKELMA contains approximately 400 mg of sodium, but the extent of absorption by the patient is unknown.

Source: FDA prescribing information (DailyMed). Set ID: 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8. SPL document ID: 5bb5ae7d-0be6-4ecc-bb31-4eedd2f724b9. Label effective date: March 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sodium Zirconium Cyclosilicate (FDA label)

LOKELMA can transiently increase gastric pH. As a result, LOKELMA can change the absorption of co-administered drugs that exhibit pH-dependent solubility, potentially leading to altered efficacy or safety of these drugs when taken close to the time LOKELMA is administered. In general, other oral medications should be administered at least 2 hours before or 2 hours after LOKELMA [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . LOKELMA is not expected to impact systemic exposure of drugs that do not exhibit pH-dependent solubility and so spacing is not needed if it has been determined that the concomitant medication does not exhibit pH-dependent solubility.

Source: FDA prescribing information (DailyMed). Set ID: 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8. SPL document ID: 5bb5ae7d-0be6-4ecc-bb31-4eedd2f724b9. Label effective date: March 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.